Upcoming Investor Conferences for Zymeworks
Zymeworks Inc. (NASDAQ: ZYME), a pioneering biotechnology firm focused on advancing novel biotherapeutics for challenging diseases, is excited to announce its participation in several high-profile investor conferences in the near future. These events will allow Zymeworks' management to engage directly with investors and stakeholders about their ongoing initiatives and the promising future of their product pipeline.
Key Events on the Calendar
Management will be present at the following investor conferences:
UBS Global Healthcare Conference
On this date, Zymeworks’ management will participate in one-on-one meetings with potential investors in California.
Stifel 2024 Healthcare Conference
Management will engage in one-on-one meetings and take part in a notable fireside chat. This is a key opportunity for investors to gain insight into the company's strategic direction.
Jefferies London Healthcare Conference
During this period, management will hold one-on-one meetings and partake in a significant discussion. This will highlight Zymeworks’ innovations and strategic advancements in the biotechnology sector.
Piper Sandler 36th Annual Healthcare Conference
The management will attend this conference for engaging meetings and presentations, allowing them to showcase their innovative therapeutic approaches.
Citi's 2024 Global Healthcare Conference
Here, Zymeworks’ management will be involved in meetings and panel discussions, specifically focused on novel mechanisms in oncology treatments.
7th Annual Evercore HealthCONx Conference
Closing out their conference participation, Zymeworks will hold meetings and engaging discussions, spotlighting their latest therapeutic advances.
The Vision Behind Zymeworks
Zymeworks is on a mission to transform the standard of care for patients facing difficult-to-treat cancers and other severe diseases. With a considerable pipeline of products, including monoclonal antibodies and innovative biotherapeutics, the company endeavors to make significant improvements in patient outcomes. They have been at the forefront of developing zanidatamab, a bispecific antibody targeting HER2, utilizing their proprietary Azymetric™ technology.
Current Developments and Partnerships
In collaboration with BeiGene and Jazz Pharmaceuticals, Zymeworks has granted exclusive rights to develop and commercialize zanidatamab in various regions. The antibody is undergoing extensive global clinical trials, with hopes of achieving the status of a best-in-class treatment for HER2-expressing cancers, particularly after the recent acceptance of its Biologics License Application (BLA) by the U.S. FDA, which seeks accelerated approval.
A Growing Pipeline
Zymeworks' commitment to innovation is exemplified by its diverse lineup of wholly-owned product candidates, including ZW171 and ZW191, which are currently in Phase 1 studies. Their robust platforms have positioned the company well for strategic partnerships with leading biopharmaceutical entities, further enhancing their therapeutic reach.
Company Contact Information
For any inquiries, Zymeworks encourages investors to reach out to the following contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Frequently Asked Questions
What is Zymeworks' focus in the biotechnology industry?
Zymeworks specializes in developing innovative biotherapeutics aimed at treating difficult diseases, particularly in oncology.
When will Zymeworks participate in the upcoming investor conferences?
Zymeworks will participate in several conferences, including the UBS and Stifel Healthcare Conferences, among others.
What is zanidatamab?
Zanidatamab is Zymeworks' bispecific antibody that targets HER2, currently under development to treat HER2-expressing cancers.
How does Zymeworks intend to improve patient care?
Zymeworks aims to make a meaningful impact on patient outcomes by advancing therapies that target specific cancer pathways.
How can I learn more about Zymeworks' projects?
Investors can visit Zymeworks' official website or follow them on social media for the latest updates and developments.
